Strata Skin SciencesFRA:E2O 38 Piotroski F-Score is 5 as of Jun. 29, 2026, which is at its 10-year median of 5.00. GuruFocus rates FRA:E2O with a GF Score™ of 38/100 and a GF Value™ of €58.84. The stock has 5 warning signs investors should review. Among 807 Medical Devices & Instruments companies, Strata Skin Sciences ranks better than 64.93% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Strata Skin Sciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Strata Skin Sciences's Piotroski F-Score or its related term are showing as below:
FRA:E2O'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 5 Max: 6
Current: 5
During the past 13 years, the highest Piotroski F-Score of Strata Skin Sciences was 6. The lowest was 2. And the median was 5.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Strata Skin Sciences Piotroski F-Score Related Terms
Strata Skin Sciences Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:E2O vs ODYY, NUMD, PFSA: Piotroski F-Score Comparison
For the Medical Devices subindustry, Strata Skin Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Strata Skin Sciences's current Net Income (TTM) was -5.74.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Strata Skin Sciences's return on assets of this year was -0.17208298. Strata Skin Sciences's return on assets of last year was -0.24423162.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Strata Skin Sciences's gearing of this year was 0.02042802. Strata Skin Sciences's gearing of last year was 0.42333196.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Strata Skin Sciences's current ratio of this year was 0.58335158. Strata Skin Sciences's current ratio of last year was 1.23880247.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Strata Skin Sciences's number of shares in issue this year was 0. Strata Skin Sciences's number of shares in issue last year was 4.174.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Strata Skin Sciences's gross margin of this year was 0.57739695. Strata Skin Sciences's gross margin of last year was 0.56955111.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Strata Skin Sciences's asset turnover of this year was 0.80297398. Strata Skin Sciences's asset turnover of last year was 0.80772924.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
1
+
0
+
1
+
1
+
0
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Strata Skin Sciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Strata Skin Sciences (FRA:E2O) has a Piotroski F-Score of 5 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Strata Skin Sciences and its competitors. This is near median its historical median of 5.00. Over the past decade, Strata Skin Sciences' Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Strata Skin Sciences ranks #283 out of 807 companies in the Medical Devices & Instruments industry, placing it in the top 35.1%.
Is Strata Skin Sciences' Piotroski F-Score too high?
Strata Skin Sciences' current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Strata Skin Sciences' value of 5 is 0% at this industry median. Based on the distribution chart, Strata Skin Sciences ranks #283 out of 807 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' Piotroski F-Score compare to ODYY and NUMD?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #283 out of 807 companies for Piotroski F-Score. This puts Strata Skin Sciences in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Strata Skin Sciences' value of 5 is 0% at this benchmark. Historically, Strata Skin Sciences' own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Strata Skin Sciences has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Skin Sciences's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Strata Skin Sciences and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current Piotroski F-Score of 5. The stock's GF Value™ is €58.84, compared to a current price of €3.76 — trading 93.6% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Medical Devices & Instruments industry median of 5.00. Strata Skin Sciences' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current Piotroski F-Score is 5 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 93.6% below its estimated GF Value™ of €58.84.
Key valuation signals for FRA:E2O:
Piotroski F-Score: 5 (near median its 10-year median of 5.00)
GF Value™: €58.84 vs. price of €3.76 (93.6% below fair value)
Industry Position: 0% at the Medical Devices & Instruments median (#283 of 807)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
